Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Operating Expenses (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Operating Expenses for 7 consecutive years, with $100.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 14.31% to $100.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $388.6 million, a 25.88% increase, with the full-year FY2025 number at $388.6 million, up 25.88% from a year prior.
  • Operating Expenses was $100.8 million for Q4 2025 at Kymera Therapeutics, up from $95.3 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $100.8 million in Q4 2025 to a low of $31.9 million in Q1 2021.
  • A 5-year average of $66.1 million and a median of $61.1 million in 2023 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: skyrocketed 147.42% in 2021, then rose 11.15% in 2022.
  • Kymera Therapeutics' Operating Expenses stood at $49.3 million in 2021, then rose by 11.16% to $54.8 million in 2022, then grew by 22.69% to $67.2 million in 2023, then skyrocketed by 31.18% to $88.1 million in 2024, then rose by 14.31% to $100.8 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Operating Expenses are $100.8 million (Q4 2025), $95.3 million (Q3 2025), and $96.0 million (Q2 2025).